SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Article in The Lancet Haematology (July 2022)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in The Lancet Haematology (July 2022)
Article in Journal of Hematology & Oncology (June 2021)
Article in Journal of Medical Economics (July 2020)